-
1
-
-
34147145338
-
Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia
-
Meshinchi S, Arceci RJ. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Oncologist 2007;12:341-55.
-
(2007)
Oncologist
, vol.12
, pp. 341-355
-
-
Meshinchi, S.1
Arceci, R.J.2
-
2
-
-
36349018880
-
Pediatric acute myeloid leukemia: Towards high-quality cure of all patients
-
Kaspers GJ, Zwaan CM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica 2007;92: 1519-32.
-
(2007)
Haematologica
, vol.92
, pp. 1519-1532
-
-
Kaspers, G.J.1
Zwaan, C.M.2
-
3
-
-
8344272920
-
Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia
-
Zwaan CM, Kaspers GJ. Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia. Br J Haematol 2004;127: 264-79.
-
(2004)
Br J Haematol
, vol.127
, pp. 264-279
-
-
Zwaan, C.M.1
Kaspers, G.J.2
-
4
-
-
0031972535
-
Ara-C: Cellular and molecular pharmacology
-
Grant S. Ara-C: cellular and molecular pharmacology. Adv Cancer Res 1998;72:197-233.
-
(1998)
Adv Cancer Res
, vol.72
, pp. 197-233
-
-
Grant, S.1
-
6
-
-
41949111045
-
Acute promyelocytic leukemia: From highly fatal to highly curable
-
Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111:2505-15.
-
(2008)
Blood
, vol.111
, pp. 2505-2515
-
-
Wang, Z.Y.1
Chen, Z.2
-
7
-
-
34447507691
-
Targeting transcription factors in acute leukemia in children
-
Berman JN, Look AT. Targeting transcription factors in acute leukemia in children. Curr Drug Targets 2007;8:727-37.
-
(2007)
Curr Drug Targets
, vol.8
, pp. 727-737
-
-
Berman, J.N.1
Look, A.T.2
-
8
-
-
30344433284
-
Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress
-
Gao N, Rahmani M, Shi X, Dent P, Grant S. Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress. Blood 2006;107:241-9.
-
(2006)
Blood
, vol.107
, pp. 241-249
-
-
Gao, N.1
Rahmani, M.2
Shi, X.3
Dent, P.4
Grant, S.5
-
9
-
-
33748427812
-
Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: A mechanism for leukemia-specific HDI-dependent apoptosis?
-
Gaymes TJ, Padua RA, Pla M, et al. Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis? Mol Cancer Res 2006;4:563-73.
-
(2006)
Mol Cancer Res
, vol.4
, pp. 563-573
-
-
Gaymes, T.J.1
Padua, R.A.2
Pla, M.3
-
10
-
-
51649126841
-
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma
-
Ellis L, Pan Y, Smyth GK, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008;14:4500-10.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 4500-4510
-
-
Ellis, L.1
Pan, Y.2
Smyth, G.K.3
-
11
-
-
21244464349
-
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
-
Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-31.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3923-3931
-
-
Kelly, W.K.1
O'Connor, O.A.2
Krug, L.M.3
-
12
-
-
4444309863
-
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with alltrans retinoic acid
-
Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with alltrans retinoic acid. Blood 2004;104:1266-9.
-
(2004)
Blood
, vol.104
, pp. 1266-1269
-
-
Kuendgen, A.1
Strupp, C.2
Aivado, M.3
-
13
-
-
33748997409
-
Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia
-
Cimino G, Lo-Coco F, Fenu S, et al. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 2006;66:8903-11.
-
(2006)
Cancer Res
, vol.66
, pp. 8903-8911
-
-
Cimino, G.1
Lo-Coco, F.2
Fenu, S.3
-
14
-
-
33750530675
-
Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia
-
Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108:3271-9.
-
(2006)
Blood
, vol.108
, pp. 3271-3279
-
-
Garcia-Manero, G.1
Kantarjian, H.M.2
Sanchez-Gonzalez, B.3
-
15
-
-
34948845116
-
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
-
Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007;110:2302-8.
-
(2007)
Blood
, vol.110
, pp. 2302-2308
-
-
Soriano, A.O.1
Yang, H.2
Faderl, S.3
-
16
-
-
34249937594
-
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: A clinical and translational study
-
Munster P, Marchion D, Bicaku E, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007;25:1979-85.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1979-1985
-
-
Munster, P.1
Marchion, D.2
Bicaku, E.3
-
17
-
-
18244383806
-
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
-
Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20:6969-78.
-
(2001)
EMBO J
, vol.20
, pp. 6969-6978
-
-
Gottlicher, M.1
Minucci, S.2
Zhu, P.3
-
18
-
-
42649109021
-
Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors
-
Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008;34:206-22.
-
(2008)
Cancer Treat Rev
, vol.34
, pp. 206-222
-
-
Duenas-Gonzalez, A.1
Candelaria, M.2
Perez-Plascencia, C.3
Perez-Cardenas, E.4
De La Cruz-Hernandez, E.5
Herrera, L.A.6
-
19
-
-
3142692649
-
Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1
-
Tang R, Faussat AM, Majdak P, et al. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 2004;18:1246-51.
-
(2004)
Leukemia
, vol.18
, pp. 1246-1251
-
-
Tang, R.1
Faussat, A.M.2
Majdak, P.3
-
20
-
-
13444274622
-
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway
-
Insinga A, Monestiroli S, Ronzoni S, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005;11:71-6.
-
(2005)
Nat Med
, vol.11
, pp. 71-76
-
-
Insinga, A.1
Monestiroli, S.2
Ronzoni, S.3
-
21
-
-
33747203758
-
Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor
-
Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, et al. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 2006;108:1174-82.
-
(2006)
Blood
, vol.108
, pp. 1174-1182
-
-
Sanchez-Gonzalez, B.1
Yang, H.2
Bueso-Ramos, C.3
-
22
-
-
20344394418
-
Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid
-
Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G. Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk Res 2005;29:739-48.
-
(2005)
Leuk Res
, vol.29
, pp. 739-748
-
-
Yang, H.1
Hoshino, K.2
Sanchez-Gonzalez, B.3
Kantarjian, H.4
Garcia-Manero, G.5
-
23
-
-
33846502110
-
The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells
-
ten Cate B, Samplonius DF, Bijma T, de Leij LF, Helfrich W, Bremer E. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. Leukemia 2007;21:248-52.
-
(2007)
Leukemia
, vol.21
, pp. 248-252
-
-
Ten Cate, B.1
Samplonius, D.F.2
Bijma, T.3
De Leij, L.F.4
Helfrich, W.5
Bremer, E.6
-
24
-
-
34347375499
-
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells
-
Miller CP, Ban K, Dujka ME, et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007; 110:267-77.
-
(2007)
Blood
, vol.110
, pp. 267-277
-
-
Miller, C.P.1
Ban, K.2
Dujka, M.E.3
-
25
-
-
24744438875
-
Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27 (Kip 1) in acute myeloblastic leukemia cells
-
Siitonen T, Koistinen P, Savolainen ER. Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27 (Kip 1) in acute myeloblastic leukemia cells. Leuk Res 2005;29: 1335-42.
-
(2005)
Leuk Res
, vol.29
, pp. 1335-1342
-
-
Siitonen, T.1
Koistinen, P.2
Savolainen, E.R.3
-
26
-
-
0033566994
-
Expression of chromosome 21-localized genes in acute myeloid leukemia: Differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin
-
Taub JW, Huang X, Matherly LH, et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood 1999;94:1393-400.
-
(1999)
Blood
, vol.94
, pp. 1393-1400
-
-
Taub, J.W.1
Huang, X.2
Matherly, L.H.3
-
27
-
-
0034889197
-
Drug synergism: Its detection and applications
-
Tallarida RJ. Drug synergism: its detection and applications. J Pharmacol Exp Ther 2001;298:865-72.
-
(2001)
J Pharmacol Exp Ther
, vol.298
, pp. 865-872
-
-
Tallarida, R.J.1
-
28
-
-
33748794547
-
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
-
Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
-
(2006)
Pharmacol Rev
, vol.58
, pp. 621-681
-
-
Chou, T.C.1
-
29
-
-
70350506780
-
RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: Role in chemotherapy sensitivity in acute megakaryocytic leukemia
-
Edwards H, Xie C, LaFiura KM, et al. RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood 2009;114:2744-52.
-
(2009)
Blood
, vol.114
, pp. 2744-2752
-
-
Edwards, H.1
Xie, C.2
LaFiura, K.M.3
-
30
-
-
13744252262
-
GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia
-
Ge Y, Stout ML, Tatman DA, et al. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. J Natl Cancer Inst 2005;97:226-31.
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 226-231
-
-
Ge, Y.1
Stout, M.L.2
Tatman, D.A.3
-
32
-
-
0343280013
-
A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage
-
Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000;10:886-95.
-
(2000)
Curr Biol
, vol.10
, pp. 886-895
-
-
Paull, T.T.1
Rogakou, E.P.2
Yamazaki, V.3
Kirchgessner, C.U.4
Gellert, M.5
Bonner, W.M.6
-
33
-
-
71949117093
-
Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: Evidence for distinct roles for Bcl-2, Bcl-xL, Mcl-1
-
Chen S, Dai Y, Pei XY, Grant S. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, Mcl-1. Mol Cell Biol 2009;29:6149-69.
-
(2009)
Mol Cell Biol
, vol.29
, pp. 6149-6169
-
-
Chen, S.1
Dai, Y.2
Pei, X.Y.3
Grant, S.4
-
34
-
-
27644556419
-
Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim
-
Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A 2005;102:16090-5.
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, pp. 16090-16095
-
-
Zhao, Y.1
Tan, J.2
Zhuang, L.3
Jiang, X.4
Liu, E.T.5
Yu, Q.6
-
35
-
-
0036201888
-
Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways
-
Kawagoe R, Kawagoe H, Sano K. Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leuk Res 2002; 26:495-502.
-
(2002)
Leuk Res
, vol.26
, pp. 495-502
-
-
Kawagoe, R.1
Kawagoe, H.2
Sano, K.3
-
36
-
-
29744454120
-
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia
-
Kuendgen A, Schmid M, Schlenk R, et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006;106:112-9.
-
(2006)
Cancer
, vol.106
, pp. 112-119
-
-
Kuendgen, A.1
Schmid, M.2
Schlenk, R.3
-
37
-
-
33750454091
-
Oral rapid loading of valproic acid - An alternative to the usual saturation scheme?
-
Gerstner T, Bell N, Longin E, Konig SA. Oral rapid loading of valproic acid - an alternative to the usual saturation scheme? Seizure 2006; 15:630-2.
-
(2006)
Seizure
, vol.15
, pp. 630-632
-
-
Gerstner, T.1
Bell, N.2
Longin, E.3
Konig, S.A.4
-
38
-
-
0347628818
-
p21Waf1/Cip1 as a therapeutic target in breast and other cancers
-
Weiss RH. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003;4:425-9.
-
(2003)
Cancer Cell
, vol.4
, pp. 425-429
-
-
Weiss, R.H.1
-
39
-
-
26244438834
-
BCL-2: Found bound and drugged!
-
Letai A. BCL-2: found bound and drugged! Trends Mol Med 2005; 11:442-4.
-
(2005)
Trends Mol Med
, vol.11
, pp. 442-444
-
-
Letai, A.1
|